Cancer Immunology and Immunotherapy

癌症免疫学和免疫治疗

• 批准号: 8724681
• 负责人: George J. Weiner
• 金额: $ 2.92万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8724681
• 关键词: Agonist; Area; B lymphoid malignancy; Basic Science; Cancer Center; Cancer Center Support Grant; Cancer Immunology Science; Cancer Vaccines; Cells; Cessation of life; Clinic; Clinical; Clinical Trials; Collaborations; Development; Faculty; Funding; Goals; Homeostasis; Human; Immune; Immune response; Immune system; Immunologist; Immunology; Immunotherapeutic agent; Immunotherapy; Individual; Infection; Instruction; Laboratories; Link; Lymphocyte; Lymphoma; MS4A1 gene; Malignant Neoplasms; Malignant lymphoid neoplasm; Malignant neoplasm of prostate; Malignant neoplasm of urinary bladder; Modeling; Molecular; Paper; Preclinical Testing; Process; Prostate Cancer Vaccine; Publications; Publishing; Research; Research Peer Review; Research Personnel; Role; Signal Transduction; Signaling Molecule; System; Therapeutic; Therapeutic antibodies; Translating; Translational Research; Tumor Necrosis Factor Receptor; Universities; base; cancer immunotherapy; college; combat; design; improved; innovation; insight; interest; member; novel strategies; programs; research clinical testing; response; stem cell biology; stem cells; trafficking; translational study; tumor

PROJECT SUMMARY (See instructions): Cancer Immunology & Immunotherapy Research in the Cancer Immunology & Immunotherapy Program is exploring basic, translational and clinical aspects of lymphoid malignancies and various approaches to cancer immunotherapy. The overall goal of the members of the program is to improve our understanding of the mechanisms of immune system-based cell signaling, differentiation, trafficking, and death with the long-term goal of enhancing our ability to treat lymphoid malignancies and induce a more effective anti-cancer immune response. The program also focuses on translating laboratory advances to the clinic through innovative clinical trials in cancer immunotherapy. There are two major overlapping themes within the Program. The first Theme is Cancer Immunology. The emphasis within this Theme is basic research in Lymphocyte Signaling, Host Responses, and Stem Cell Biology. The emphasis of the complementary translational Cancer Immunotherapy Theme is upon Immunotherapy of Lymphoid Malignancies and Cancer Vaccines. Major accomplishments of the Cancer Immunology and Immunotherapy Program over the past funding period include understanding the roles of signaling molecules, including TNFR-associated factors (TRAFs), in lymphoid malignancies, analysis of the mechanisms of action of ahti-CD20 therapeutic antibodies, development of TLR9 agonists as immunotherapeutic agents, and development of a prostate cancer vaccine. There are numerous past and present productive collaborations both between members of the Program, and with members of other Cancer Center programs. Most notable are the collaborative, translational studies taking place through the Lymphoma SPORE. The program consists of 28 members from 1 basic science and 5 clinical departments and 1 College. Peer-reviewed, research funding forthis program totals $9.6 million with $1.5 million coming from the NCI. Program members published 322 cancer-related papers over the prior funding period. Ofthese publications, 16% were intraprogrammatic, 15% were interprogrammatic and 4% were both intra and interprogrammatic, for a total of 36% collaborative publications.

项目摘要（请参阅说明）： 癌症免疫学和免疫疗法 癌症免疫学和免疫疗法计划的研究正在探索淋巴恶性肿瘤的基本，转化和临床方面以及癌症免疫疗法的各种方法。该计划成员的总体目标是提高我们对基于免疫系统的细胞信号，分化，贩运和死亡机制的理解，其长期目标是增强我们治疗淋巴性恶性肿瘤的能力，并诱导更有效的抗癌免疫反应。该计划还致力于通过癌症免疫疗法的创新临床试验将实验室进步转化为诊所。 该程序中有两个主要的重叠主题。第一个主题是癌症免疫学。该主题的重点是淋巴细胞信号，宿主反应和干细胞生物学的基础研究。补充转化癌免疫疗法主题的重点是淋巴恶性肿瘤和癌症疫苗的免疫疗法。癌症的主要成就 在过去的资金期间，免疫学和免疫疗法计划包括了解信号分子的作用，包括与TNFR相关的因素（TRAF），在淋巴恶性肿瘤中，分析AHTI-CD20治疗性抗体的作用机制，TLR9调动主义者作为免疫疗法的促进性和癌症的发育，以及癌症的发展。有很多过去， 该计划成员之间以及其他癌症中心计划的成员之间的生产性合作。最值得注意的是通过淋巴瘤孢子进行的协作，翻译研究。该计划由来自1个基础科学和5个临床系和1所大学的28名成员组成。 同行评审的研究资助计划总计960万美元，NCI的150万美元。 计划成员在以前的资金期间发表了322篇与癌症有关的论文。这些出版物是16％的术中，15％是诠释截图的，4％既有内部和诠释式媒介物，总共有36％的协作出版物。